Regeneron's bid to acquire the bankrupt genetic testing firm 23andMe for $256 million has likely come to an end.

Genetic testing company 23andMe can proceed with a $305 million sale to the company’s co-founder Anne Wojcicki after a U.S.

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of $256 million, a company spokesperson told Reuters on Monday.

Anne Wojcicki, founder and former CEO of 23andMe, will helm the company again after her nonprofit's purchase was approved.

Now that the data is going to a 23andMe-adjacent nonprofit, which is also making similar promises, I guess nothing much has ...

When popular genetic testing company 23andMe filed for bankruptcy earlier this year and announced it was for sale, privacy ...

That means Wojcicki’s nonprofit TTAM Research Institute will purchase “substantially all” of San Francisco-based 23andMe’s ...

A bankruptcy court gave the green light for TTAM Research Institute - a firm launched by 23andMe's co-founder and former CEO ...

The DNA data of millions of people who used 23andMe's services won't be sold to a pharmaceutical company. A bankruptcy judge ...

-Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of $256 million, a company spokesperson told Reuters on Monday ...